자폐스펙트럼장애 역학 분석과 예측(2026년)

The Global Autism Spectrum Disorder prevelance is set to reach USD 80.8 million patients in 2035, growing at a CAGR of 1.8% from USD 68.6 million patients in 2026.

The global autism spectrum disorder (ASD) epidemiology analysis market has become an increasingly important component of the neurodevelopmental disorders research landscape as healthcare systems, pharmaceutical companies, research institutions, and policymakers seek comprehensive insights into the prevalence, incidence, disease burden, demographic distribution, and long-term healthcare needs associated with autism spectrum disorder. Epidemiological analysis provides the foundation for clinical research, healthcare planning, therapeutic development, and public health policy by identifying patient populations, disease trends, diagnostic patterns, and unmet medical needs. Growing awareness of autism, expanding diagnostic capabilities, and improvements in disease surveillance continue to increase the demand for high-quality epidemiological data.

The market encompasses prevalence analysis, incidence estimation, patient population forecasting, demographic segmentation, disease burden assessment, risk factor evaluation, comorbidity analysis, and geographic distribution studies. Pharmaceutical companies and biotechnology firms utilize epidemiological data to support drug development strategies, clinical trial planning, market opportunity assessments, and commercialization activities. Governments, healthcare providers, academic institutions, and public health organizations rely on epidemiological insights to allocate healthcare resources, develop screening programs, and improve access to early intervention services.

Growing advances in healthcare data analytics, electronic health records, artificial intelligence, genetic research, and disease registries have significantly enhanced the quality and accuracy of autism epidemiology studies. Increasing adoption of standardized diagnostic criteria, broader screening initiatives, and improved healthcare access have contributed to greater identification of individuals across the autism spectrum, enabling more comprehensive epidemiological assessments. At the same time, continued research into genetic susceptibility, environmental influences, and neurodevelopmental biology is expanding understanding of ASD risk factors and population characteristics.

The market is further supported by increasing investment in autism research, expanding international collaborations, and rising demand for evidence-based healthcare planning. As autism prevalence continues to receive greater global attention and healthcare systems prioritize early diagnosis and lifelong support services, epidemiological analysis is expected to remain an essential component of strategic decision-making throughout the forecast period.

Market Drivers

Rising Prevalence of Autism Spectrum Disorder

The increasing number of diagnosed individuals with ASD is driving demand for comprehensive epidemiological analysis. Improved awareness, expanded screening programs, and evolving diagnostic criteria have contributed to higher diagnosis rates, requiring detailed assessment of disease burden and patient demographics.

Growing Focus on Early Diagnosis

Healthcare systems worldwide are emphasizing early developmental screening and timely intervention. Epidemiological studies support healthcare planning by identifying trends in diagnosis, age distribution, and population-level healthcare needs.

Increasing Investment in Autism Research

Governments, research organizations, academic institutions, and pharmaceutical companies continue to increase investments in autism-related research. Epidemiological analysis supports clinical development, healthcare policy formulation, and long-term resource planning.

Expansion of Healthcare Data Infrastructure

The adoption of electronic health records, disease registries, digital health platforms, and advanced analytics is improving the availability and quality of epidemiological data. These technologies enable more accurate patient population analysis and disease forecasting.

Growing Demand for Public Health Planning

Healthcare policymakers increasingly rely on epidemiological data to evaluate disease burden, allocate healthcare resources, expand specialized services, and improve long-term support programs for individuals with autism spectrum disorder.

Market Restraints

Variability in Diagnostic Practices

Differences in diagnostic criteria, screening methodologies, healthcare access, and reporting systems across countries create challenges for standardized epidemiological analysis and international comparisons.

Underdiagnosis in Developing Regions

Limited awareness, shortages of specialists, and restricted access to developmental assessment services continue to contribute to underdiagnosis in several low- and middle-income countries, reducing data completeness.

Data Collection Challenges

Accurate epidemiological analysis depends on comprehensive patient registries, standardized reporting systems, and long-term surveillance. Inconsistent data collection methods can affect analytical accuracy.

Limited Longitudinal Data

Long-term population studies remain limited in many regions, making it difficult to evaluate disease progression, lifetime outcomes, and changes in prevalence over extended periods.

Privacy and Regulatory Considerations

The collection and analysis of patient-level healthcare data require compliance with evolving privacy regulations and ethical standards, increasing operational complexity for epidemiological research.

Technology and Segment Insights

The autism spectrum disorder epidemiology analysis market can be segmented by epidemiological study type, demographic category, application, end user, and geographic coverage.

By Epidemiological Study Type

Prevalence analysis represents the largest segment because it provides estimates of the total number of individuals living with autism spectrum disorder within defined populations. These studies are essential for healthcare planning and market forecasting.

Incidence analysis evaluates newly diagnosed cases over specified periods and supports understanding of disease trends and screening effectiveness.

Disease burden analysis examines disability, healthcare utilization, quality of life, and economic impact, helping policymakers prioritize healthcare investments.

Risk factor and comorbidity analysis continues to expand as researchers investigate genetic, environmental, developmental, and medical factors associated with autism spectrum disorder.

By Demographic Category

Pediatric populations account for the largest share of epidemiological research because autism is typically diagnosed during early childhood and developmental years.

Adolescent population studies focus on educational outcomes, behavioral development, and transition into adult healthcare services.

Adult autism epidemiology is becoming increasingly important as healthcare systems recognize the long-term support needs of individuals across the lifespan.

Gender-based epidemiological studies continue to receive attention as researchers investigate differences in diagnosis rates, symptom presentation, and healthcare utilization.

By Application

Clinical trial planning represents a major application, with epidemiological analysis supporting patient recruitment strategies, site selection, and market opportunity assessment.

Healthcare policy development utilizes epidemiological data to guide funding decisions, screening programs, and specialized healthcare service expansion.

Commercial market forecasting helps pharmaceutical and biotechnology companies evaluate future treatment demand and investment opportunities.

Academic research institutions employ epidemiological analysis to investigate disease mechanisms, population characteristics, and long-term health outcomes.

By End User

Pharmaceutical companies represent a significant end-user segment because epidemiological data support pipeline prioritization, commercial planning, and regulatory submissions.

Government agencies and public health organizations utilize epidemiological studies for healthcare planning, disease surveillance, and policy development.

Academic institutions and research organizations contribute substantially through population-based studies, disease registries, and international collaborative research initiatives.

Healthcare providers and specialty autism centers increasingly rely on epidemiological data to optimize service delivery and resource allocation.

By Geographic Coverage

North America represents a leading market due to established surveillance systems, extensive healthcare databases, and high levels of autism research investment.

Europe continues to strengthen epidemiological research through national registries and collaborative public health initiatives.

Asia Pacific is experiencing rapid growth as awareness improves, healthcare infrastructure expands, and diagnostic capabilities increase across emerging economies.

Latin America, the Middle East, and Africa are gradually expanding epidemiological research through improved healthcare access and international collaboration.

Competitive and Strategic Outlook

The competitive landscape includes healthcare analytics companies, epidemiology research organizations, academic institutions, pharmaceutical companies, contract research organizations, public health agencies, and market intelligence providers. Competition is increasingly focused on delivering comprehensive epidemiological datasets, advanced forecasting models, artificial intelligence-enabled analytics, and real-world evidence that support clinical and commercial decision-making.

Organizations are investing in digital health technologies, electronic health record integration, predictive analytics, machine learning, genetic databases, and population health platforms to improve the quality and accuracy of epidemiological analysis. Strategic collaborations among healthcare providers, government agencies, research institutions, and pharmaceutical companies continue to expand access to high-quality patient data and strengthen epidemiological research capabilities.

As autism research continues to evolve, organizations capable of providing reliable epidemiological forecasting, demographic analysis, disease burden assessment, and real-world evidence are expected to strengthen their competitive positions. Growing emphasis on precision medicine, early diagnosis, and population health management will further increase demand for comprehensive epidemiological intelligence throughout the forecast period.

Conclusion

The global autism spectrum disorder epidemiology analysis market is expected to experience sustained growth during the forecast period, driven by increasing autism prevalence, expanding research investment, advances in healthcare data analytics, and growing demand for evidence-based healthcare planning. Improved disease surveillance, standardized diagnostic practices, and enhanced data collection technologies are strengthening the quality of epidemiological research and supporting more informed clinical and commercial decision-making. Although challenges related to diagnostic variability, data availability, and healthcare access remain, continued advances in population health research and digital analytics are expected to drive long-term market expansion. Epidemiology analysis will remain an essential foundation for autism research, healthcare policy, therapeutic development, and strategic planning across the global neurodevelopmental disorders landscape.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Global ASD Epidemiology Overview
• 1.4 Disease Burden Highlights
• 1.5 Key Epidemiological Trends
• 1.6 Diagnosis and Screening Trends
• 1.7 Strategic Insights
• 1.8 Future Outlook (2025-2045)

2. Autism Spectrum Disorder Disease Overview

• 2.1 Introduction to Autism Spectrum Disorder (ASD)
• 2.2 Disease Definition and Classification
  • 2.2.1 Autism Spectrum Disorder Level 1
  • 2.2.2 Autism Spectrum Disorder Level 2
  • 2.2.3 Autism Spectrum Disorder Level 3
  • 2.2.4 Syndromic Autism
  • 2.2.5 Non-Syndromic Autism
• 2.3 Etiology and Risk Factors
• 2.4 Genetic and Environmental Factors
• 2.5 Pathophysiology Overview
• 2.6 Signs and Symptoms
• 2.7 Disease Burden and Societal Impact
• 2.8 Diagnostic Criteria and Assessment Tools
• 2.9 Challenges in Diagnosis and Early Detection

3. Research Methodology and Epidemiology Assumptions

• 3.1 Study Methodology
• 3.2 Data Collection Framework
• 3.3 Epidemiology Modeling Approach
• 3.4 Forecasting Methodology
• 3.5 Data Validation and Triangulation
• 3.6 Key Assumptions and Limitations

4. Global Autism Spectrum Disorder Epidemiology Overview

• 4.1 Global Prevalence Analysis (2025-2045)
• 4.2 Global Incidence Analysis (2025-2045)
• 4.3 Diagnosed Patient Population
• 4.4 Undiagnosed Patient Population
• 4.5 Disease Severity Distribution
• 4.6 Gender-Specific Epidemiology
• 4.7 Age-Specific Epidemiology
• 4.8 Epidemiology Forecast Analysis

5. Patient Population Segmentation

• 5.1 By Disease Severity
  • 5.1.1 Level 1 ASD
  • 5.1.2 Level 2 ASD
  • 5.1.3 Level 3 ASD
• 5.2 By Disease Type
  • 5.2.1 Syndromic Autism
  • 5.2.2 Non-Syndromic Autism
• 5.3 By Gender
  • 5.3.1 Male Population
  • 5.3.2 Female Population
• 5.4 By Age Group
  • 5.4.1 Children (0-5 Years)
  • 5.4.2 Children (6-12 Years)
  • 5.4.3 Adolescents (13-17 Years)
  • 5.4.4 Adults (18-44 Years)
  • 5.4.5 Older Adults (?45 Years)
• 5.5 By Diagnosis Status
  • 5.5.1 Diagnosed Population
  • 5.5.2 Undiagnosed Population
  • 5.5.3 Early Diagnosed Population
  • 5.5.4 Late Diagnosed Population
• 5.6 By Care Setting
  • 5.6.1 Hospitals
  • 5.6.2 Specialty Neurodevelopmental Centers
  • 5.6.3 Community Care Settings
  • 5.6.4 Home-Based Care

6. Epidemiological Trends and Disease Burden

• 6.1 Historical Epidemiology Trends
• 6.2 Disease Burden Analysis
• 6.3 Disability Burden Assessment
• 6.4 Educational and Social Impact
• 6.5 Family and Caregiver Burden
• 6.6 Healthcare Resource Utilization
• 6.7 Long-Term Epidemiological Trends

7. Diagnosis and Screening Landscape

• 7.1 Diagnostic Pathway Analysis
• 7.2 Early Screening Trends
• 7.3 Age at Diagnosis Assessment
• 7.4 Diagnostic Tools Utilization
• 7.5 Barriers to Early Diagnosis
• 7.6 Regional Diagnosis Variability
• 7.7 Future Diagnosis Trends

8. Comorbidity and Associated Conditions Analysis

• 8.1 Intellectual Disability
• 8.2 Attention Deficit Hyperactivity Disorder (ADHD)
• 8.3 Anxiety Disorders
• 8.4 Depression
• 8.5 Epilepsy
• 8.6 Sleep Disorders
• 8.7 Gastrointestinal Disorders
• 8.8 Other Neurodevelopmental Disorders

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Total Prevalence
  • 9.1.2 Total Incidence
  • 9.1.3 Diagnosed Cases
  • 9.1.4 Disease Severity Distribution
  • 9.1.5 Age-Specific Epidemiology
  • 9.1.6 Gender-Specific Epidemiology
  • 9.1.7 Forecast Analysis (2025-2045)
• 9.2 Europe
  • 9.2.1 Total Prevalence
  • 9.2.2 Total Incidence
  • 9.2.3 Diagnosed Cases
  • 9.2.4 Disease Severity Distribution
  • 9.2.5 Age-Specific Epidemiology
  • 9.2.6 Gender-Specific Epidemiology
  • 9.2.7 Forecast Analysis (2025-2045)
• 9.3 Asia-Pacific
  • 9.3.1 Total Prevalence
  • 9.3.2 Total Incidence
  • 9.3.3 Diagnosed Cases
  • 9.3.4 Disease Severity Distribution
  • 9.3.5 Age-Specific Epidemiology
  • 9.3.6 Gender-Specific Epidemiology
  • 9.3.7 Forecast Analysis (2025-2045)
• 9.4 Latin America
  • 9.4.1 Total Prevalence
  • 9.4.2 Total Incidence
  • 9.4.3 Diagnosed Cases
  • 9.4.4 Disease Severity Distribution
  • 9.4.5 Age-Specific Epidemiology
  • 9.4.6 Gender-Specific Epidemiology
  • 9.4.7 Forecast Analysis (2025-2045)
• 9.5 Middle East & Africa
  • 9.5.1 Total Prevalence
  • 9.5.2 Total Incidence
  • 9.5.3 Diagnosed Cases
  • 9.5.4 Disease Severity Distribution
  • 9.5.5 Age-Specific Epidemiology
  • 9.5.6 Gender-Specific Epidemiology
  • 9.5.7 Forecast Analysis (2025-2045)

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Total Prevalence
  • 10.1.2 Total Incidence
  • 10.1.3 Diagnosed Cases
  • 10.1.4 Disease Severity Distribution
  • 10.1.5 Age-Specific Epidemiology
  • 10.1.6 Gender-Specific Epidemiology
  • 10.1.7 Forecast Analysis (2025-2045)
• 10.2 Canada
  • 10.2.1 Total Prevalence
  • 10.2.2 Total Incidence
  • 10.2.3 Diagnosed Cases
  • 10.2.4 Disease Severity Distribution
  • 10.2.5 Age-Specific Epidemiology
  • 10.2.6 Gender-Specific Epidemiology
  • 10.2.7 Forecast Analysis (2025-2045)
• 10.3 Germany
  • 10.3.1 Total Prevalence
  • 10.3.2 Total Incidence
  • 10.3.3 Diagnosed Cases
  • 10.3.4 Disease Severity Distribution
  • 10.3.5 Age-Specific Epidemiology
  • 10.3.6 Gender-Specific Epidemiology
  • 10.3.7 Forecast Analysis (2025-2045)
• 10.4 United Kingdom
  • 10.4.1 Total Prevalence
  • 10.4.2 Total Incidence
  • 10.4.3 Diagnosed Cases
  • 10.4.4 Disease Severity Distribution
  • 10.4.5 Age-Specific Epidemiology
  • 10.4.6 Gender-Specific Epidemiology
  • 10.4.7 Forecast Analysis (2025-2045)
• 10.5 France
  • 10.5.1 Total Prevalence
  • 10.5.2 Total Incidence
  • 10.5.3 Diagnosed Cases
  • 10.5.4 Disease Severity Distribution
  • 10.5.5 Age-Specific Epidemiology
  • 10.5.6 Gender-Specific Epidemiology
  • 10.5.7 Forecast Analysis (2025-2045)
• 10.6 Italy
  • 10.6.1 Total Prevalence
  • 10.6.2 Total Incidence
  • 10.6.3 Diagnosed Cases
  • 10.6.4 Disease Severity Distribution
  • 10.6.5 Age-Specific Epidemiology
  • 10.6.6 Gender-Specific Epidemiology
  • 10.6.7 Forecast Analysis (2025-2045)
• 10.7 Spain
  • 10.7.1 Total Prevalence
  • 10.7.2 Total Incidence
  • 10.7.3 Diagnosed Cases
  • 10.7.4 Disease Severity Distribution
  • 10.7.5 Age-Specific Epidemiology
  • 10.7.6 Gender-Specific Epidemiology
  • 10.7.7 Forecast Analysis (2025-2045)
• 10.8 China
  • 10.8.1 Total Prevalence
  • 10.8.2 Total Incidence
  • 10.8.3 Diagnosed Cases
  • 10.8.4 Disease Severity Distribution
  • 10.8.5 Age-Specific Epidemiology
  • 10.8.6 Gender-Specific Epidemiology
  • 10.8.7 Forecast Analysis (2025-2045)
• 10.9 Japan
  • 10.9.1 Total Prevalence
  • 10.9.2 Total Incidence
  • 10.9.3 Diagnosed Cases
  • 10.9.4 Disease Severity Distribution
  • 10.9.5 Age-Specific Epidemiology
  • 10.9.6 Gender-Specific Epidemiology
  • 10.9.7 Forecast Analysis (2025-2045)
• 10.10 India
  • 10.10.1 Total Prevalence
  • 10.10.2 Total Incidence
  • 10.10.3 Diagnosed Cases
  • 10.10.4 Disease Severity Distribution
  • 10.10.5 Age-Specific Epidemiology
  • 10.10.6 Gender-Specific Epidemiology
  • 10.10.7 Forecast Analysis (2025-2045)
• 10.11 South Korea
  • 10.11.1 Total Prevalence
  • 10.11.2 Total Incidence
  • 10.11.3 Diagnosed Cases
  • 10.11.4 Disease Severity Distribution
  • 10.11.5 Age-Specific Epidemiology
  • 10.11.6 Gender-Specific Epidemiology
  • 10.11.7 Forecast Analysis (2025-2045)
• 10.12 Australia
  • 10.12.1 Total Prevalence
  • 10.12.2 Total Incidence
  • 10.12.3 Diagnosed Cases
  • 10.12.4 Disease Severity Distribution
  • 10.12.5 Age-Specific Epidemiology
  • 10.12.6 Gender-Specific Epidemiology
  • 10.12.7 Forecast Analysis (2025-2045)

11. Unmet Needs and Future Epidemiology Trends

• 11.1 Diagnostic Challenges
• 11.2 Early Detection Gaps
• 11.3 Regional Epidemiology Disparities
• 11.4 Healthcare Access Challenges
• 11.5 Future Disease Burden Outlook
• 11.6 Emerging Epidemiological Trends
• 11.7 Strategic Recommendations

12. Company Profiles

• 12.1 Roche
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 Autism Diagnostics and Research Portfolio
  • 12.1.4 Neurodevelopmental Research Strategy
  • 12.1.5 Epidemiology and Biomarker Initiatives
  • 12.1.6 Strategic Collaborations
  • 12.1.7 Key Programs
  • 12.1.8 Recent Developments
• 12.2 Quest Diagnostics
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 Autism Diagnostics Portfolio
  • 12.2.4 Neurodevelopmental Testing Strategy
  • 12.2.5 Epidemiology and Screening Programs
  • 12.2.6 Strategic Collaborations
  • 12.2.7 Key Programs
  • 12.2.8 Recent Developments
• 12.3 Labcorp
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 Autism Diagnostics Portfolio
  • 12.3.4 Neurodevelopmental Testing Strategy
  • 12.3.5 Epidemiology and Screening Programs
  • 12.3.6 Strategic Collaborations
  • 12.3.7 Key Programs
  • 12.3.8 Recent Developments
• 12.4 GeneDx
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Autism Diagnostics Portfolio
  • 12.4.4 Genetic Testing Strategy
  • 12.4.5 Epidemiology and Screening Programs
  • 12.4.6 Strategic Collaborations
  • 12.4.7 Key Programs
  • 12.4.8 Recent Developments
• 12.5 Natera, Inc.
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Neurodevelopmental Testing Portfolio
  • 12.5.4 Genetic Testing Strategy
  • 12.5.5 Epidemiology and Screening Programs
  • 12.5.6 Strategic Collaborations
  • 12.5.7 Key Programs
  • 12.5.8 Recent Developments
• 12.6 Ambry Genetics
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Autism Diagnostics Portfolio
  • 12.6.4 Genetic Testing Strategy
  • 12.6.5 Epidemiology and Screening Programs
  • 12.6.6 Strategic Collaborations
  • 12.6.7 Key Programs
  • 12.6.8 Recent Developments
• 12.7 Bionano Genomics
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Neurodevelopmental Research Portfolio
  • 12.7.4 Genomic Analysis Strategy
  • 12.7.5 Epidemiology Initiatives
  • 12.7.6 Strategic Collaborations
  • 12.7.7 Key Programs
  • 12.7.8 Recent Developments
• 12.8 Illumina, Inc.
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Neurodevelopmental Genomics Portfolio
  • 12.8.4 Precision Diagnostics Strategy
  • 12.8.5 Epidemiology Initiatives
  • 12.8.6 Strategic Collaborations
  • 12.8.7 Key Programs
  • 12.8.8 Recent Developments
• 12.9 Thermo Fisher Scientific Inc.
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Neurodevelopmental Genomics Portfolio
  • 12.9.4 Precision Diagnostics Strategy
  • 12.9.5 Epidemiology Initiatives
  • 12.9.6 Strategic Collaborations
  • 12.9.7 Key Programs
  • 12.9.8 Recent Developments
• 12.10 Revvity, Inc.
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Neurodevelopmental Diagnostics Portfolio
  • 12.10.4 Precision Diagnostics Strategy
  • 12.10.5 Epidemiology Initiatives
  • 12.10.6 Strategic Collaborations
  • 12.10.7 Key Programs
  • 12.10.8 Recent Developments

13. Future Outlook and Strategic Recommendations

• 13.1 Future Prevalence Outlook
• 13.2 Future Incidence Outlook
• 13.3 Screening and Diagnosis Evolution
• 13.4 Biomarker and Genetic Research Impact
• 13.5 Healthcare Infrastructure Development
• 13.6 Strategic Recommendations
• 13.7 Long-Term Epidemiology Outlook (2025-2045)

14. Appendix

• 14.1 Abbreviations
• 14.2 Glossary of Terms
• 14.3 References
• 14.4 List of Tables
• 14.5 List of Figures
• 14.6 Epidemiology Sources
• 14.7 Government and Public Health Sources
• 14.8 Company Sources